Boris Duchemann

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Pulmonary Fibrosis

Community Dwelling

Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Translational lung cancer research

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Boris Duchemann, Emmanuelle Fabre, Jordi Remon
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib. Translational lung cancer research 13 (4) (2024)
Boris Duchemann, Emmanuelle Fabre, Jordi Remon
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib. Translational lung cancer research 13 (4) (2024)
Marie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, Lisa Boselli, Jean-Mehdi Jouniaux, Caroline de Oliveira, Roberto Ferrara, Boris Duchemann, Caroline Berthot, Lou Girard, Ronan Flippot, Laurence Albiges, Siham Farhane, Patrick Saulnier, Ludovic Lacroix, Frank Griscelli, Gabriel Roman, Tyler Hulett, Aurélien Marabelle, Lydie Cassard, Benjamin Besse, Nathalie Chaput
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8 + T cells in patients with advanced NSCLC. Science advances 9 (45) (2023)
Ana Oliveira, Gaia Fabbri, Thomas Gille, Elena Bargagli, Boris Duchemann, Rachel Evans, Hilary Pinnock, Anne Elizabeth Holland, Elisabetta Renzoni, Magnus Per Ekström, Steve Jones, Marlies Wijsenbeek, Anh Tuan Dinh-Xuan, Guido Vagheggini
Holistic management of patients with progressive pulmonary fibrosis. Breathe (Sheffield, England) 19 (3) (2023)
Julia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, Jean-Baptiste Assié, Laurence Champion, Nicolas Girard, Gerald Bonardel, Lise Matton, Michael Soussan, Christos Chouaid, Boris Duchemann
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers 15 (8) (2023)
Julia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, Jean-Baptiste Assié, Laurence Champion, Nicolas Girard, Gerald Bonardel, Lise Matton, Michael Soussan, Christos Chouaid, Boris Duchemann
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers 15 (8) (2023)
Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, François-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurélien Marabelle, Benjamin Besse, Nathalie Chaput
CD8 + PD-1 + to CD4 + PD-1 + ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. Journal for immunotherapy of cancer 10 (2) (2022)
Julie Lasvergnas, Marie Naigeon, Kader Chouahnia, Laurent Zelek, Nathalie Chaput, Boris Duchemann
Adoptive cell therapies in thoracic malignancies. Cancer immunology, immunotherapy : CII 71 (9) (2022)
Boris Duchemann, Gregory Lazarian
Post-SARS-CoV-2 vaccination acute hemolysis in an older man: don't forget to look at the blood smear. Blood 138 (21) (2021)
Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers 13 (20) (2021)
Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann, Laura Mezquita, Nicolas Girard, Laurence Champion
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers 12 (8) (2020)
Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita, Matthieu Texier, Caroline Caramella, Lizza E L Hendriks, David Planchard, Jordi Remon, Sabina Sangaletti, Claudia Proto, Marina C Garassino, Jean-Charles Soria, Aurélien Marabelle, Anne-Laure Voisin, Siham Farhane, Benjamin Besse, Nathalie Chaput
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (2) (2020)
Sanjana Monirul, Marthe Rigal, Kader Chouahnia, Mélisande Le Jouan, Maxime Apparuit, Adrien Paix, Anne Jacolot, Laurent Zelek, Boris Duchemann
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines 8 (4) (2020)
Boris Duchemann, Jordi Remon, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers 12 (12) (2020)
Gabrielle Archer, Boris Duchemann, Stephane Gaudry, Yacine Tandjaoui-Lambiotte
Spectacular improvement of lung computer tomography after treatment with EGFR tyrosine kinase inhibitor for miliary carcinomatosis. Intensive care medicine 45 (10) (2019)